Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder.

Literature DB >> 19593186

The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder.

Margaret M McClure, Harold W Koenigsberg, Diedre Reynolds, Marianne Goodman, Antonia New, Robert Trestman, Jeremy Silverman, Philip D Harvey, Larry J Siever.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19593186 PMCID： PMC4176874 DOI： 10.1097/JCP.0b013e3181accfd9

Source DB: PubMed Journal: J Clin Psychopharmacol ISSN： 0271-0749 Impact factor: 3.153

× No keyword cloud information.

15 in total

1. Attentional functioning in schizotypal personality disorder.

Authors: S E Roitman; B A Cornblatt; A Bergman; M Obuchowski; V Mitropoulou; R S Keefe; J M Silverman; L J Siever
Journal: Am J Psychiatry Date: 1997-05 Impact factor: 18.112

2. The factor structure of schizotypal symptoms in a clinical population.

Authors: A J Bergman; P D Harvey; V Mitropoulou; A Aronson; D Marder; J Silverman; R Trestman; L J Siever
Journal: Schizophr Bull Date: 1996 Impact factor: 9.306

Review 3. The primacy of cognition in schizophrenia.

Authors: R Walter Heinrichs
Journal: Am Psychol Date: 2005-04

4. Guanfacine treatment of cognitive impairment in schizophrenia.

Authors: J I Friedman; D N Adler; H D Temporini; E Kemether; P D Harvey; L White; M Parrella; K L Davis
Journal: Neuropsychopharmacology Date: 2001-09 Impact factor: 7.853

Review 5. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Authors: Neil D Woodward; Scot E Purdon; Herbert Y Meltzer; David H Zald
Journal: Int J Neuropsychopharmacol Date: 2005-03-23 Impact factor: 5.176

6. Visuospatial working memory in schizotypal personality disorder patients.

Authors: S E Roitman; V Mitropoulou; R S Keefe; J M Silverman; M Serby; P D Harvey; D A Reynolds; R C Mohs; L J Siever
Journal: Schizophr Res Date: 2000-02-14 Impact factor: 4.939

7. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Authors: Robert M Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Journal: Am J Psychiatry Date: 2002-06 Impact factor: 18.112

8. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

Authors: Peter Milev; Beng-Choon Ho; Stephan Arndt; Nancy C Andreasen
Journal: Am J Psychiatry Date: 2005-03 Impact factor: 18.112

9. Risperidone in the treatment of schizotypal personality disorder.

Authors: Harold W Koenigsberg; Diedre Reynolds; Marianne Goodman; Antonia S New; Vivian Mitropoulou; Robert L Trestman; Jeremy Silverman; Larry J Siever
Journal: J Clin Psychiatry Date: 2003-06 Impact factor: 4.384

10. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Authors: Richard S E Keefe; Robert M Bilder; Sonia M Davis; Philip D Harvey; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; George Capuano; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Clarence E Davis; John K Hsiao; Jeffrey A Lieberman
Journal: Arch Gen Psychiatry Date: 2007-06

3 in total